ERG and cancer: Mohamed et al. demonstrated that elevated levels of the TMPRSS2-ERG fusion protein found in prostate cancer, can decrease HPGD expression by binding to the HPGD promoter, resulting in PGE2-dependent cancer proliferation and invasion [45].